Becton, Dickinson and Company Prices Offerings Of $2.25 Billion Of Common Stock And $2.25 Billion Of Depositary Shares Representing Interests In Mandatory Convertible Preferred Stock Post author:Sam Post published:May 10, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like 3 FDA Decisions to Look Out for in February January 31, 2018 FDA's Has Big Plans to Get Drugs Approved Faster, Tackle Drug Development Costs September 11, 2017 AstraZeneca PLC Forges $400 Million Parkinson's R&D Deal With Takeda August 28, 2017